Literature DB >> 30395047

Laparoscopic Endoscopic Cooperative Surgery for Gastrointestinal Stromal Tumors.

Honglei Wang1, Lei Cao, Kunming Zheng, Yongjie Zhao.   

Abstract

With the development of laparoscopy and digestive endoscopy, multiple laparoscopic and endoscopic cooperative surgeries (LECSs) for gastrointestinal stromal tumors have recently been developed. Classic LECS has been confirmed as a feasible and safe treatment procedure for gastrointestinal stromal tumors with regard to both short-term surgical and long-term oncological outcomes; however, classic LECS has the potential risk of gastric contents or tumor cells spilling into the abdominal cavity because the gastric wall has to be opened during the procedure. Various modified LECS techniques have aimed at further minimizing invasiveness, such as the full-thickness resection method using the nonexposure technique (combination of laparoscopic and endoscopic approaches to neoplasia with a nonexposure technique), nonexposed endoscopic wall-inversion surgery, and closed LECS. This review describes and summarizes the current LECS for gastrointestinal tumor.

Entities:  

Mesh:

Year:  2018        PMID: 30395047     DOI: 10.1097/SLE.0000000000000591

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  3 in total

1.  Factors Affecting the Length of Hospitalization after Laparoscopic Resection of Gastric Subepithelial Tumor.

Authors:  Yeon Soo Chang
Journal:  J Minim Invasive Surg       Date:  2019-09-15

Review 2.  Lap-Endo cooperative surgery (LECS) in gastric GIST: updates and future advances.

Authors:  Thomas Zheng Jie Teng; Farhan Ishraq; Amelia Fang Ting Chay; Kon Voi Tay
Journal:  Surg Endosc       Date:  2022-10-11       Impact factor: 3.453

3.  Multiband mucosectomy versus endoscopic submucosal dissection and endoscopic submucosal excavation for GI submucosal tumors: short and long term follow-up.

Authors:  Xi-Feng Jin; Wei Gai; Rong-Lian Du; Tong-Hai Chai; Ling Li; Christoph J Auernhammer
Journal:  BMC Cancer       Date:  2019-09-06       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.